Defining the molecular pathology of pancreatic body and tail adenocarcinoma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) remains a dismal disease, with very little improvement in survival over the past 50 years. Recent large-scale genomic studies have improved understanding of the genomic and transcriptomic landscape of the disease, yet very little is known about molecular heterogeneity according to tumour location in the pancreas; body and tail PDACs especially tend to have a significantly worse prognosis. The aim was to investigate the molecular differences between PDAC of the head and those of the body and tail of the pancreas. Methods: Detailed correlative analysis of clinicopathological variables, including tumour location, genomic and transcriptomic data, was performed using the Australian Pancreatic Cancer Genome Initiative (APGI) cohort, part of the International Cancer Genome Consortium study. Results: Clinicopathological data were available for 518 patients recruited to the APGI, of whom 421 underwent genomic analyses; 179 of these patients underwent whole-genome and 96 RNA sequencing. Patients with tumours of the body and tail had significantly worse survival than those with pancreatic head tumours (12·1 versus 22·0 months; P = 0·001). Location in the body and tail was associated with the squamous subtype of PDAC. Body and tail PDACs enriched for gene programmes involved in tumour invasion and epithelial-to-mesenchymal transition, as well as features of poor antitumour immune response. Whether this is due to a molecular predisposition from the outset, or reflects a later time point on the tumour molecular clock, requires further investigation using well designed prospective studies in pancreatic cancer. Conclusion: PDACs of the body and tail demonstrate aggressive tumour biology that may explain worse clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationWhole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citationHidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Self-citationA renewed model of pancreatic cancer evolution based on genomic rearrangement patterns
Notta, F., Chan-Seng-Yue, M., Lemire, M., Li, Y., Wilson, G. W., Connor, A. A., Denroche, R. E., Liang, S.-B., Brown, A. M. K., Kim, J. C., et al. (2016) · Nature · doi:10.1038/nature19823 · Cited by 528
Kim, S., Lahmy, R., Riha, C., Yang, C., Jakubison, B. L., van Niekerk, J., Staub, C., Wu, Y., Gates, K., Dong, D. S., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000328 · Cited by 48
Research works printed but not linked: 21
- Garrido-Laguna, 2015, Pancreatic cancer: from state-of-the-art treatments to promising novel therapies, Nat Rev Clin Oncol, 12, 319, 10.1038/nrclinonc.2015.53 · DOI · Paper page
- Neoptolemos, 2017, Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial, Lancet, 389, 1011, 10.1016/S0140-6736(16)32409-6 · DOI · Paper page
- Artinyan, 2008, The anatomic location of pancreatic cancer is a prognostic factor for survival, HPB (Oxford), 10, 371, 10.1080/13651820802291233 · DOI · Paper page
- Brennan, 1996, Management of adenocarcinoma of the body and tail of the pancreas, Ann Surg, 223, 506, 10.1097/00000658-199605000-00006 · DOI · Paper page
- Watanabe, 2004, Onset symptoms and tumor locations as prognostic factors of pancreatic cancer, Pancreas, 28, 160, 10.1097/00006676-200403000-00007 · DOI
- Sener, 1999, Pancreatic cancer: a report of treatment and survival trends for 100 313 patients diagnosed from 1985–1995, using the National Cancer Database, J Am Coll Surg, 189, 1, 10.1016/S1072-7515(99)00075-7 · DOI · Paper page
- Lau, 2010, Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States, Pancreas, 39, 458, 10.1097/MPA.0b013e3181bd6489 · DOI · Paper page
- Sohn, 2000, Resected adenocarcinoma of the pancreas – 616 patients: results, outcomes, and prognostic indicators, J Gastrointest Surg, 4, 567, 10.1016/S1091-255X(00)80105-5 · DOI · Paper page
- Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 · DOI · Paper page
- Collisson, 2011, Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy, Nat Med, 17, 500, 10.1038/nm.2344 · DOI · Paper page
- Fang, 2017, Genomic signatures of pancreatic adenosquamous carcinoma (PASC), J Pathol, 243, 155, 10.1002/path.4943 · DOI
- Hoadley, 2014, Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin, Cell, 158, 929, 10.1016/j.cell.2014.06.049 · DOI · Paper page
- Li, 2009, Fast and accurate short read alignment with Burrows–Wheeler transform, Bioinformatics, 25, 1754, 10.1093/bioinformatics/btp324 · DOI · Paper page
- Bland, 2004, The logrank test, BMJ, 328, 1073, 10.1136/bmj.328.7447.1073 · DOI · Paper page
- Cox, 1972, Regression models and life-tables, J R Stat Soc B, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x · DOI · Paper page
- Groot, 2017, Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma
- Kuhlmann, 2017, Identification and validation of novel subtype-specific protein biomarkers in pancreatic ductal adenocarcinoma, Pancreas, 46, 311, 10.1097/MPA.0000000000000743 · DOI
- Noll, 2016, CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma, Nat Med, 22, 278, 10.1038/nm.4038 · DOI · Paper page
- Biankin, 2009, Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer, Gastroenterology, 137, 558, 10.1053/j.gastro.2009.04.009 · DOI
- Chang, 2011, A molecular prognostic nomogram for resectable pancreatic cancer, J Clin Oncol, 29, 154, 10.1200/jco.2011.29.4_suppl.154 · doi:10.1200/jco.2011.29.4_suppl.154
- Steele, 2016, CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma, Cancer Cell, 29, 832, 10.1016/j.ccell.2016.04.014 · DOI · Paper page
Cited by
Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer
Halbrook, C. J., Pontious, C., Kovalenko, I., Lapienyte, L., Dreyer, S., Lee, H.-J., Thurston, G., Zhang, Y., Lazarus, J., Sajjakulnukit, P., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.001 · Cited by 419
Self-citationMota Reyes, C., Teller, S., Muckenhuber, A., Konukiewitz, B., Safak, O., Weichert, W., Friess, H., Ceyhan, G. O., & Demir, I. E. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1864 · Cited by 80
Miura, S., Takikawa, T., Kikuta, K., Hamada, S., Kume, K., Yoshida, N., Tanaka, Y., Matsumoto, R., Ikeda, M., Kataoka, F., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11091693 · Cited by 38
Metadata
- Authors
- Initiative, A. P. C. G., Dreyer, S. B., Jamieson, N. B., Upstill-Goddard, R., Bailey, P. J., McKay, C. J., Biankin, A. V., & Chang, D. K.
- Venue
- British Journal of Surgery
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01
- Volume
- 105
- Issue
- 2
- Pages
- e183-e191
- ISSN
- 0007-1323 (ISSN-L)
- 1365-2168
- OpenAlex
- W2784433219
- Cited by
- 122
- References
- 9
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining the molecular pathology of pancreatic body and tail adenocarcinoma. https://app.cochat.ai/papers/10.1002/bjs.10772
- The paper
- Initiative, A. P. C. G., Dreyer, S. B., Jamieson, N. B., Upstill-Goddard, R., Bailey, P. J., McKay, C. J., Biankin, A. V., & Chang, D. K. (2018). Defining the molecular pathology of pancreatic body and tail adenocarcinoma. British Journal of Surgery. https://doi.org/10.1002/bjs.10772
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.